Hybrid closed loop technology was associated with superior efficacy and safety outcomes relative to standard insulin therapy in T1D.

A drug for treating diabetes similar to popular weight-loss medicines such as Ozempic did not show any benefits for people ...

We expect Novo to gain $75 billion of a more than $200 billion global GLP-1 market in diabetes and obesity by 2031, ahead of semaglutide's 2032 patent expiration, with Lilly standing as the firm's key ...

Novo Nordisk has a dominant position in diabetes and weight-loss drugs, strong financial growth outlook, and great potential. Click to read why NVO is a Strong Buy.

Families want nurse or staff to monitor apps remotely in case of urgent alarms; schools cite shrinking budgets and internet ...

Novel approach designed to offer a more personalized and effective treatment option for patients suffering from diabetes and ...

One of the most exciting developments in diabetes treatment is the use of new medications that help control blood sugar in ...

Wegovy is a GLP-1 agonist containing semaglutide, the same active ingredient as Ozempic. While both medications share this ...

If you’re in Australia, BellyBelly recommends THESE doctors and specialists to help manage your gestational diabetes. After giving birth, breastfeeding is encouraged. Most women will no longer need ...

People with diabetes are especially prone to side effects from cortisone injections ... The peak elevation tends to occur anywhere from 5 to 84 hours after the injection. If you self-administer ...

Those theories included: • Michael being on medication for diabetes, but he wasn’t ... which no other diagnosis but an insulin injection fit, was low potassium levels. Krieger said low ...